• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Nov 12, 2026 | Press Releases

Highlighting Phio’s Differentiated, Paradigm-Shifting Treatment Approach for Skin CancerLive Presentation and Q&A: Wednesday, November 18, 2026 2 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – November 12, 2026) – Phio...

Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting

Nov 9, 2026 | Press Releases

INTASYL siRNA – Redefining the Treatment Paradigm for Cutaneous Squamous Cell Carcinoma; Potential to Decrease Morbidities and Surgical FatigueKing of Prussia, Pennsylvania–(Newsfile Corp. – November 9, 2026) – Phio Pharmaceuticals Corp....

Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

Nov 6, 2026 | Press Releases

INTASYL siRNA – Redefining the Treatment Paradigm for Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania–(Newsfile Corp. – November 6, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation

Nov 5, 2026 | Press Releases

PH-762 Program Accomplishes Major Development Milestones Including Completion of Commercial-Scale cGMP Manufacturing, Treatment in Long-Term Toxicology Study, and Submission of Key Regulatory Documents to FDAKing of Prussia, Pennsylvania–(Newsfile Corp. –...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Oct 19, 2026 | Press Releases

Live Presentation and Q&A: Tuesday, October 20, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – October 19, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Oct 13, 2026 | Press Releases

Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania–(Newsfile Corp. – October 13, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a...
« Older Entries

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
  • Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
  • Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2026 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us